TY - JOUR T1 - A Genomic Survey of SARS-CoV-2 Reveals Multiple Introductions into Northern California without a Predominant Lineage JF - medRxiv DO - 10.1101/2020.03.27.20044925 SP - 2020.03.27.20044925 AU - Xianding Deng AU - Wei Gu AU - Scot Federman AU - Louis du Plessis AU - Oliver G. Pybus AU - Nuno Faria AU - Candace Wang AU - Guixia Yu AU - Chao-Yang Pan AU - Hugo Guevara AU - Alicia Sotomayor-Gonzalez AU - Kelsey Zorn AU - Allan Gopez AU - Venice Servellita AU - Elaine Hsu AU - Steve Miller AU - Trevor Bedford AU - Alexander L. Greninger AU - Pavitra Roychoudhury AU - Lea M. Starita AU - Michael Famulare AU - Helen Y. Chu AU - Jay Shendure AU - Keith R. Jerome AU - Catie Anderson AU - Karthik Gangavarapu AU - Mark Zeller AU - Emily Spencer AU - Kristian G. Andersen AU - Duncan MacCannell AU - Clinton R. Paden AU - Yan Li AU - Jing Zhang AU - Suxiang Tong AU - Gregory Armstrong AU - Scott Morrow AU - Matthew Willis AU - Bela T. Matyas AU - Sundari Mase AU - Olivia Kasirye AU - Maggie Park AU - Curtis Chan AU - Alexander T. Yu AU - Shua J. Chai AU - Elsa Villarino AU - Brandon Bonin AU - Debra A. Wadford AU - Charles Y. Chiu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/30/2020.03.27.20044925.abstract N2 - The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has spread globally, resulting in >300,000 reported cases worldwide as of March 21st, 2020. Here we investigate the genetic diversity and genomic epidemiology of SARS-CoV-2 in Northern California using samples from returning travelers, cruise ship passengers, and cases of community transmission with unclear infection sources. Virus genomes were sampled from 29 patients diagnosed with COVID-19 infection from Feb 3rd through Mar 15th. Phylogenetic analyses revealed at least 8 different SARS-CoV-2 lineages, suggesting multiple independent introductions of the virus into the state. Virus genomes from passengers on two consecutive excursions of the Grand Princess cruise ship clustered with those from an established epidemic in Washington State, including the WA1 genome representing the first reported case in the United States on January 19th. We also detected evidence for presumptive transmission of SARS-CoV-2 lineages from one community to another. These findings suggest that cryptic transmission of SARS-CoV-2 in Northern California to date is characterized by multiple transmission chains that originate via distinct introductions from international and interstate travel, rather than widespread community transmission of a single predominant lineage. Rapid testing and contact tracing, social distancing, and travel restrictions are measures that will help to slow SARS-CoV-2 spread in California and other regions of the USA.Competing Interest StatementCYC is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support funding from Abbott Laboratories. CYC and XD are inventors on a patent application on the MSSPE method titled “Spiked Primer Design for Targeted Enrichment of Metagenomic Libraries” (US Application No. 62/667,344, filed 05/04/2018 by University of California, San Francisco). HYC is a consultant for Merck and GlaxoSmithKline, and receives research funding from Sanofi-Pasteur, Ellume and Cepheid, unrelated to this work. All other authors have no conflicts to declare. The opinions expressed by the authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated. Funding StatementThis work was funded by NIH grants R33-AI129455 (CYC) from the National Institute of Allergy and Infectious Diseases, the Charles and Helen Schwab Foundation (CYC), K08-CA230156 (WG), and the Burroughs-Wellcome CAMS Award (WG).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe assembled SARS-CoV-2 genomes in this study were uploaded to GISAID (28-29) as FASTA files, and can be visualized on a continually updated phylogenetic tree on NextStrain (30). Submission of the genomes and raw sequence data to NIH GenBank and Sequence Read Archive (SRA) is pending https://www.gisaid.org/epiflu-applications/next-hcov-19-app/ ER -